Last reviewed · How we verify
NCT06246695
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
Phase 1 trial testing Jaktinib Hydrochloride Tablets in Healthy Volunteers in 40 participants. Completed in 12 January 2022.
12 January 2022
Quick facts
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 27 October 2021 |
| Primary completion | 12 January 2022 |
| Estimated completion | 12 January 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Jaktinib Hydrochloride Tablets — full drug profile →
- Itraconazole capsule — full drug profile →
- Rifampicin Capsules — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study was to assess the effect of rifampicin and itraconazole, on the pharmacokinetics (PK) of Jaktinib in healthy Volunteers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06246695
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Jaktinib Hydrochloride Tablets
Trials testing the same drug.
- NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
- NCT04993404 — Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function · Phase 1 · completed
- NCT04851535 — Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. · Phase 2 · completed
- NCT04507659 — Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis · Phase 2 · completed
- NCT04312594 — Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis · Phase 2 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials
Trials by the same sponsor.
- NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
- NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
- NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06246695 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246695.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing